Manufacturing / Pharmaceutical Preparations
Erasca, Inc.
ERAS
$15.95
+$0.55 (+3.54%)
Price as of Oct 9, 2026 18:52 UTC
6.2 B
Market Cap (Mid Cap)
11%
IV Rank
105.7%
Implied Volatility
Nov 10
Next Earnings
Technical Signals
as of Oct 7
Mixed
3 of 7
Trend
- Above 20-day average $15.01
- Above 50-day average $15.92
- Above 200-day average $13.90 · +1.6%
- Moving averages stacked Not aligned
Momentum
- Golden cross (50/200) —
- Momentum cross (20/50) Down · 19d ago
Volume
- Below-average volume 0.8x avg
Price & Trend
Daily candles with EMA 20, SMA 50. Drag to zoom.
Options Activity & Greeks
Implied volatility, flow, and dealer positioning from the options market.
Put/Call Ratio
4.73
Bearish skew
Implied Volatility
105.7%
0% percentile
IV vs Realized
Options rich
30d HV 59.3%
Options Heat Map
Delta-risk grid for ERAS options across strikes and expirations. Hover any cell for full Greeks.
Loading option chain data...
Insider Trades
0 buys
3 sells
| Date | Insider | Title | Type | Shares | Value | Since Trade |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Fuchs Charles S. | Grant | 1,300,000 | $0 | -14.7% | |
| Apr 01, 2026 | Garner Ebun | Exercise | 80,000 | $0 | -6.9% | |
| Apr 01, 2026 | Garner Ebun | Sell | 80,000 | $1,312,000 | -5.7% | |
| Apr 01, 2026 | Garner Ebun | Exercise | 80,000 | $136,000 | +809.4% | |
| Mar 04, 2026 | Morris Shannon | Exercise | 20,000 | $34,000 | +809.4% | |
| Mar 04, 2026 | Morris Shannon | Sell | 20,000 | $300,760 | +2.8% | |
| Jan 29, 2026 | Chacko David M. | Grant | 640,000 | $0 | +50.0% | |
| Jan 29, 2026 | Varney Michael David | Grant | 96,000 | $0 | +50.0% | |
| Jan 29, 2026 | Garner Ebun | Grant | 560,000 | $0 | +50.0% | |
| Jan 29, 2026 | Lim Jonathan E | Grant | 2,000,000 | $0 | +50.0% |
Earnings History
| Date | Quarter | EPS Est. | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Aug 10, 2026 | Q2 2026 | -$0.12 | |||
| Aug 06, 2026 | Q2 2026 | -$0.12 |
Track ERAS with ThetaPal
Get insider trade alerts, AI portfolio analysis, and options roll recommendations for ERAS and your entire portfolio.